$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
卡博替尼治疗甲状腺髓样癌推荐剂量
2025-10-19 11:44:20
Check Details
多吉美获批治疗分化型甲状腺癌
2025-10-19 11:44:20
Check Details
索拉非尼为甲状腺癌患者提供新选择
2025-10-19 11:44:20
Check Details
乐伐替尼治疗转移性甲状腺癌的的效果显著
2025-10-19 11:44:20
Check Details
酮康唑对乐伐替尼在健康人群中药代动力学的影响
2025-10-19 11:44:20
Check Details
多吉美治疗分化型甲状腺癌的安全性
2025-10-19 11:44:20
Check Details
乐伐替尼治疗放射性碘难治性分化型甲状腺癌
2025-10-19 11:44:20
Check Details
索拉非尼延长转移性甲状腺癌患者生存期
2025-10-19 11:44:20
Check Details
乐伐替尼治疗分化型甲状腺癌安全有效
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌客观缓解率为65%
2025-10-19 11:44:20
Check Details
仑伐替尼治疗分化型甲状腺癌的效果
2025-10-19 11:44:20
Check Details
乐伐替尼治疗老年分化型甲状腺癌患者
2025-10-19 11:44:20
Check Details
1
2
...
2442
2443
2444
2445
2446
2447
2448
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
7
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
8
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
9
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
10
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
11
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
12
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights